2024
Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso
Somé A, Conrad M, Kabré Z, Fofana A, Yerbanga R, Bazié T, Neya C, Somé M, Kagambega T, Legac J, Garg S, Bailey J, Ouédraogo J, Rosenthal P, Cooper R. Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso. Antimicrobial Agents And Chemotherapy 2024, 68: e01534-23. PMID: 38411062, PMCID: PMC10989024, DOI: 10.1128/aac.01534-23.Peer-Reviewed Original ResearchResistance to antifolatesUncomplicated malariaEx vivo drug susceptibilityArtemisinin partial resistanceMonthly sulfadoxine-pyrimethaminePfcrt K76TPfK13 propeller domainResistance-mediating polymorphismsSeasonal malaria chemopreventionTreating uncomplicated malariaResistance to cycloguanilHigh-level resistancePlasmodium falciparum</i>A581GA613S mutationsPfdhps mutationsPfmdr1 N86YArtemether-lumefantrineK76TSulfadoxine-pyrimethamineMalaria chemopreventionPrevent malariaBobo-DioulassoDrug susceptibilityPrincipal therapy
2023
Tracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study
Ehrlich H, Somé A, Bazié T, Ebou C, Dembélé E, Balma R, Goodwin J, Wade M, Bei A, Ouédraogo J, Foy B, Dabiré R, Parikh S. Tracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study. The Lancet Microbe 2023, 4: e461-e469. PMID: 37086737, PMCID: PMC10365133, DOI: 10.1016/s2666-5247(23)00063-0.Peer-Reviewed Original ResearchConceptsMosquito blood mealsAntimalarial drug resistanceSurvey 3Blood-fed mosquitoesBlood samplesSurvey 1Survey 2Blood mealDrug resistanceUltrasensitive quantitative PCRHuman blood samplesCross-sectional studyMargin of equivalenceStrong surveillance systemCross-sectional surveySupplementary Materials sectionMarker of clonalityPragmatic thresholdAntimalarial resistanceDrug susceptibilityInfectious diseasesPlasmodium falciparumNational InstituteTolerabilityMaterial section
2007
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial
Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, Guiguemde R, Rosenthal P, Ouedraogo J. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. The Lancet 2007, 369: 491-498. PMID: 17292769, DOI: 10.1016/s0140-6736(07)60236-0.Peer-Reviewed Original ResearchConceptsUncomplicated falciparum malariaTreatment failureUncomplicated malariaArtemether-lumefantrineRecurrent parasitaemiaFalciparum malariaNew infectionsArtemisinin-based combination treatmentLate treatment failureEarly treatment failureNon-inferiority trialSymptomatic malariaEffective regimensPrimary endpointCombination regimensStandard dosesAvailable regimenCombination treatmentDrug susceptibilityPatientsAmodiaquineMalarial treatmentMalariaRegimensBobo-Dioulasso
1998
Assessment of halofantrine therapeutic effectiveness and in vitro antimalarial drug susceptibility in burkina faso
Ouedraogo J, Tinto H, Coulibaly S, Guiguemde T. Assessment of halofantrine therapeutic effectiveness and in vitro antimalarial drug susceptibility in burkina faso. Parasitology International 1998, 47: 117. DOI: 10.1016/s1383-5769(98)80251-1.Peer-Reviewed Original Research